ERBB2 and breast cancer: Concurrent mRNA expression of CD147 and CD276 in HER2+ BC patients was associated with poor disease-free survival (DFS) and overall survival (OS) rates (p = 0.01 and 0.02, respectively) (Fig. 5b).